Exelixis has filed a patent for a method of treating cancer, specifically solid tumors, using cabozantinib in combination with an immune checkpoint inhibitor or an anti-cancer vaccine. The patent also includes a method for predicting a patient’s response to this treatment by measuring the myeloid cell and T cell populations in a tumor tissue sample and associating them with the treatment response. GlobalData’s report on Exelixis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Exelixis, Cancer treatment biomarkers was a key innovation area identified from patents. Exelixis's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a method of predicting cancer treatment response
A recently filed patent (Publication Number: US20230314440A1) describes methods for predicting treatment response, identifying candidates for treatment, and treating cancer using a combination therapy of cabozantinib with an immune checkpoint inhibitor or a cancer vaccine. The methods involve analyzing the myeloid cell and T cell populations in a tumor tissue sample from a subject and associating their relative abundance/percentage with the treatment response or potential benefit from the therapy.
The patent claims cover various aspects of the methods, including predicting treatment response, identifying candidates for treatment, and treating cancer. The methods involve analyzing the myeloid cell and T cell populations in a tumor tissue sample and determining their relative abundance/percentage. Based on this analysis, the methods can predict the treatment response of a subject, identify subjects who may benefit from the therapy, and administer the combination therapy to treat cancer.
The patent also specifies the use of specific immune checkpoint inhibitors, such as inhibitors of PD-1 or PD-L1, including antibodies like anti-PD-1 or anti-PD-L1 antibodies. It further includes specific examples of immune checkpoint inhibitors, such as ipilimumab, nivolumab, pembrolizumab, cemiplimab, durvalumab, atezolizumab, or avelumab.
Additionally, the patent mentions the use of specific markers for the myeloid cell and T cell populations, such as CD68 for myeloid cells and CD8 for T cells. The presence or levels of these markers in the tumor tissue sample can indicate the responsiveness of the tumor to the combination therapy.
The patent also provides dosage ranges for administering cabozantinib, ranging from 20 to 60 mg, with specific dosages of 40 or 60 mg mentioned.
The methods described in the patent are applicable to various types of cancer, including clear cell renal cell carcinoma.
In summary, the patent describes methods for predicting treatment response, identifying candidates for treatment, and treating cancer using a combination therapy of cabozantinib with an immune checkpoint inhibitor or a cancer vaccine. The methods involve analyzing the myeloid cell and T cell populations in a tumor tissue sample and associating their relative abundance/percentage with treatment response or potential benefit. The patent also specifies the use of specific immune checkpoint inhibitors, markers for the cell populations, dosage ranges for cabozantinib, and applicable cancer types.
To know more about GlobalData’s detailed insights on Exelixis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
